Wire · opportunities
U.S. FDA Approves Ziihera® (zanidatamab-hrii) with and without Tislelizumab plus ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 26 August 2026 · Fusion42 review
The U.S. FDA approved Ziihera® (zanidatamab-hrii) with and without tislelizumab plus chemotherapy for first-line treatment of adults with HER2-positive advanced gastroesophageal adenocarcinoma (GEA), establishing a new standard of care regardless of PD-L1 status.
This Wire brief sits within Fusion42's coverage of Biotech, and 8 sources have reported it between 25 Aug 2026 and 26 Aug 2026.
◆ ◆ The Wire takeaway
FDA approval changes treatment for HER2-positive gastroesophageal cancer, meaning you must update clinical strategies or drug development plans to include zanidatamab combinations. That new standard widens patient eligibility and raises the bar for competitors.
◆ Coverage
8 sources · first reported 25 Aug 2026 · latest 26 Aug 2026
◆ Topics